MaxCyte (MXCT) has released an update.
MaxCyte, Inc., a leader in cell engineering technologies, has announced Ali Soleymannezhad as their new Chief Commercial Officer, tasked with expanding the company’s market presence in the cell and gene therapy sector. Soleymannezhad’s promotion follows a successful tenure as Executive Vice President of Bioprocessing and brings over two decades of experience to his new role. The company is poised for growth, banking on Soleymannezhad’s expertise to enhance adoption of their ExPERT Platform and provide comprehensive support to customers.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
